Stocks and Investing Stocks and Investing
Thu, November 17, 2022
Wed, November 16, 2022

Robyn Karnauskas Initiated (ABCL) at Strong Buy and Held Target at $29 on, Nov 16th, 2022


Published on 2024-10-28 00:12:55 - WOPRAI, Robyn Karnauskas
  Print publication without navigation


Robyn Karnauskas of Truist Securities, Initiated "AbCellera Biologics Inc." (ABCL) at Strong Buy and Held Target at $29 on, Nov 16th, 2022.

Robyn has made no other calls on ABCL in the last 4 months.



There are 3 other peers that have a rating on ABCL. Out of the 3 peers that are also analyzing ABCL, 0 agree with Robyn's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Robyn


  • Puneet Souda of "SVB Leerink" Maintained at Buy with Increased Target to $20 on, Wednesday, November 9th, 2022
  • Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $34 on, Wednesday, August 10th, 2022
  • Do Kim of "Piper Sandler" Maintained at Buy with Increased Target to $22 on, Tuesday, July 26th, 2022

Contributing Sources